Octodon degus: A model for the cognitive impairment associated with alzheimer's disease

CNS Neuroscience and Therapeutics

Volumn 19, Issue 9, 2013, Pages 643-648

  Tarragon, Ernesto ^a,b   Lopez, Dolores ^b   Estrada, Cristina ^a   Ana, Gonzalez Cuello ^b   Schenker, Esther ^c   Pifferi, Fabien ^d   Bordet, Regis ^e   Richardson, Jill C ^f   Herrero, Maria Trinidad ^a,b  

^a UNIVERSITAT JAUME I   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^e UNIV LILLE   (France)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Alzheimer disease; Amyloid beta protein; Memory; Mild Cognitive Impairment; Octodon degus

Indexed keywords

AMYLOID BETA PROTEIN;

AGING; ALZHEIMER DISEASE; ANIMAL MODEL; ARTICLE; CELL LOSS; CLINICAL FEATURE; COGNITIVE DEFECT; NONHUMAN; OCTODON; OCTODON DEGUS; RISK ASSESSMENT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; MEMORY; MILD COGNITIVE IMPAIRMENT; OCTODON DEGUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; OCTODON;

EID: 84882821999     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12125     Document Type: Article

References (76)

1. Haak N, Peters M. Pilgrimages in partnering with palliative care. Alzheimers Care Today 2004;5:300-312.
2. Moghekar A, Rao S, Li M, et al. Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro. J Biol Chem 2011;286:15989-15997.
3. Park SH, Kim JH, Bae SS, et al. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation. Biochem Biophys Res Commun 2011;408:602-608.
4. Leuner K, Schütt T, Kurz C, et al. Mitochondria-derived ROS lead to enhanced amyloid beta formation. Antioxid Redox Signal 2012;16:1421-1433.
5. Asberom T, Zhao Z, Bara TA, et al. Discovery of gamma-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease. Bioorg Med Chem Lett 2007;17:511-516.
6. Filali M, Lalonde R, Theriault P, Julien C, Calon F, Planel E. Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD). Behav Brain Res 2012;234:334-342.
7. Howlett DR, Richardson JC. The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP? Histol Histopathol 2009;24:83-100.
8. Chishti MA, Yang DS, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001;276:21562-21570.
9. Jawhar S, Wirths O, Schilling S, Graubner S, Demuth H-U, Bayer T. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Ab formation, induces behavioural deficits, and glutaminyl cyclase knock-out rescues the behavioural phenotype in 59FAD mice. J Biol Chem 2006;286:4454-4460.
10. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 2003;39:409-421.
11. Gonzalo-Ruiz A, Pérez JL, Sanz JM, Geula C, Arévalo J. Effects of lipids and aging on the neurotoxicity and neuronal loss caused by intracerebral injections of the amyloid-beta peptide in the rat. Exp Neurol 2006;197:41-55.
12. Stepanichev MY, Moiseeva YV, Lazareva NA, Onufriev MV, Gulyaeva NV. Single intracerebroventricular administration of amyloid-beta (25-35) peptide induces impairment in short-term rather than long-term memory in rats. Brain Res Bull 2003;61:197-205.
13. Braidy N, Muñoz P, Palacios AG, et al. Recent rodent models for Alzheimer's disease: clinical implications and basic research. J Neural Transm 2012;119:173-195.
14. Hock BJ Jr, Lamb B. Transgenic mouse models of Alzheimer's disease. Trends Genet 2011;17:S7-S12.
15. Small SA, Duff K. Linking A-beta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008;60:534-542.
16. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377:1019-1031.
17. Götz J, Streffer JR, David D, et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry 2004;9:664-683.
18. Romberg C, Mattson MP, Mughal MR, Bussey T, Saksida L. Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). J Neurosci 2011;31:3500-3507.
19. Esiri MM, Chance SA. Vulnerability to Alzheimer's pathology in neocortex: the roles of plasticity and columnar organization. J Alzheimers Dis 2006;9:79-89.
20. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A. Neuron loss in APP transgenic mice. Nature 1998;395:755-756.
21. Otalora BB, Vivanco P, Madariaga AM, Madrid JA, Rol MA. Internal temporal order in the circadian system of a dual-phasing rodent, the Octodon degus. Chronobiol Int 2010;27:1564-1579.
22. Vivanco P, López-Espinoza A, Madariaga AM, Rol MA, Madrid JA. Nocturnalism induced by scheduled feeding in diurnal Octodon degus. Chronobiol Int 2010;27:233-250.
23. Colonnello V, Iacobucci P, Fuchs T, Newberry RC, Panksepp J. Octodon degus. A useful animal model for social-affective neuroscience research: basic description of separation distress, social attachments and play. Neurosci Biobehav Rev 2010;35:1854-1863.
24. Seidel K, Poeggel G, Holetschka R, Helmeke C, Braun K. Paternal deprivation affects the development of corticotrophin-releasing factor-expressing neurones in prefrontal cortex, amygdala and hippocampus of the biparental Octodon degus. J Neuroendocrinol 2011;23:1166-1176.
25. Lee TM. Octodon degus: a diurnal, social, and long-lived rodent. ILAR J 2004;45:14-24.
26. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011;221:555-563.
27. Reyes AE, Chacoón MA, Dinamarca MC, Cerpa W, Morgan C, Inestrosa NC. Acetylcholinesterase-Aβ complexes are more toxic than Aβ fibrils in rat hippocampus: effect on rat β-amyloid aggregation, laminin expression, reactive astrocytosis and neuronal cell loss. Am J Pathol 2004;164:2163-2174.
28. Inestrosa NC, Reyes AE, Chacón MA, et al. Human-like rodent amyloid-beta-peptide determines Alzheimer pathology in aged wild-type Octodon degu. Neurobiol Aging 2005;26:1023-1028.
29. van Groen T, Kadish I, Popović N, et al. Age-related brain pathology in Octodon degu: blood vessel, white matter and Alzheimer-like pathology. Neurobiol Aging 2011;32:1651-1661.
30. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
31. Masters CL, Selkoe DJ. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006262.
32. Tanemura K, Murayama M, Akagi T, Hashikawa T, Tominaga T, Ichikawa K. Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J Neurosci 2002;22:133-141.
33. Ardiles AO, Tapia-Rojas CC, Mandal M, et al. Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease. Proc Natl Acad Sci USA 2012;109:13835-13840.
34. Jugovac D, Cavallero C. Twenty-four hours of total sleep deprivation selectively impairs attentional networks. Exp Psychol 2011;1:1-9.
35. McEwen BS. Sleep deprivation as a neurobiologic and physiologic stressor: allostasis and allostatic load. Metabolism 2006;55:S20-S23.
36. Huber R, Ghilardi MF, Massimini M, Tononi G. Local sleep and learning. Nature 2004;430:78-81.
37. Walker M, Stickgold P. Sleep-dependent learning and memory consolidation. Neuron 2004;44:121-133.
38. Palchykova S, Crestani F, Meerlo P, Tobler I. Sleep deprivation and daily torpor impair object recognition in Djungarian hamsters. Physiol Behav 2006;87:144-153.
39. Alhaider IA, Aleisa AM, Tran TT, Alkadhi KA. Sleep deprivation prevents stimulation-induced increases of levels of P-CREB and BDNF: protection by caffeine. Mol Cell Neurosci 2011;46:742-751.
40. Alzoubi KH, Khabour OF, Rashid BA, Damaj IM, Salah HA. The neuroprotective effect of vitamin E on chronic sleep deprivation-induced memory impairment: the role of oxidative stress. Behav Brain Res 2012;226:205-210.
41. Dodds CM, Bullmore ET, Henson RN, et al. Effects of donepezil on cognitive performance after sleep deprivation. Hum Psychopharmacol 2011;26:578-587.
42. Kas MJ, Edgar DM. Circadian timed wakefulness at dawn opposes compensatory sleep responses after sleep deprivation in Octodon degus. Sleep 1999;22:1045-1053.
43. Mu Q, Nahas Z, Johnson K, et al. Decreased cortical response to verbal working memory following sleep deprivation. Sleep 2005;28:55-67.
44. Bliwise DL. Sleep disorders in Alzheimer's disease and other dementias. Clin Cornerstone 2004;6:S16-S28.
45. Srinivasan V, Kaur C, Pandi-Perumal S, Brown G, Cardinali D. Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value. Int J Alzheimers Dis 2011;2011:741974.
46. Vivanco P, Ortiz V, Rol MA, Madrid JA. Looking for the keys to diurnality downstream from the circadian clock: role of melatonin in a dual-phasing rodent, Octodon degus. J Pineal Res 2007;42:280-290.
47. Sánchez-Benavides G, Gómez-Ansón B, Quintana M, et al. Problem-solving abilities and frontal lobe cortical thickness in healthy aging and mild cognitive impairment. J Int Neuropsychol Soc 2010;16:836-845.
48. Jacobs HIL, Van Boxtel MPJ, Jolles J, Verhey FRJ, Uylings HBM. Parietal cortex matters in Alzheimer's disease: an overview of structural, functional and metabolic findings. Neurosci Biobehav Rev 2012;36:297-309.
49. Laczó J, Andel R, Vyhnalek M, et al. Human analogue of the morris water maze for testing subjects at risk of Alzheimer's disease. Neurodegener Dis 2010;7:148-152.
50. Stonnington CM, Locke DEC, Dueck AC, Caselli RJ. Anxiety affects cognition differently in healthy apolipoprotein E ε4 homozygotes and non-carriers. J Neuropsychiatry Clin Neurosci 2011;23:294-299.
51. Vloeberghs E, Van Dam D, Franck F, Staufenbiel M, De Deyn PP. Mood and male sexual behaviour in the APP23 model of Alzheimer's disease. Behav Brain Res 2007;180:146-151.
52. Gallagher D, Coen R, Kilroy D, et al. Anxiety and behavioural disturbance as markers of prodromal Alzheimer's disease in patients with mild cognitive impairment. Int J Geriatr Psychiatry 2011;26:166-172.
53. Silvestrini M, Viticchi G, Falsetti L, et al. The role of carotid atherosclerosis in Alzheimer's disease progression. J Alzheimers Dis 2011;25:719-726.
54. Yarchoan M, Xie SX, Kling MA, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 2012;135:3749-3756.
55. Homan R, Hanselman JC, Bak-Mueller S, et al. Atherosclerosis in Octodon degus (degu) as a model for human disease. Atheroschlerosis 2010;212:48-54.
56. Fujisawa K, Katakami N, Kaneto H, et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atheroschlerosis 2013;227:425-428.
57. Boguszewski P, Zagrodzka J. Emotional changes related to age in rats - a behavioral analysis. Behav Brain Res 2002;133:323-332.
58. Torras-Garcia M, Costa-Miserachs D, Coll-Andreu M, Portell-Cortés I. Decreased anxiety levels related to aging. Exp Brain Res 2005;164:177-184.
59. Ramos A. Animal models of anxiety: do I need multiple tests? Trends Pharmacol Sci 2008;29:493-498.
60. Popović N, Baño-Otálora B, Rol MA, Caballero-Bleda M, Madrid JA, Popović M. Aging and time-of-day effects on anxiety in female Octodon degus. Behav Brain Res 2009;200:117-121.
61. Wilks SE, Little KG, Gough HR, Spurlock WJ. Alzheimer's aggression: influences on caregiver coping and resilience. J Gerontol Soc Work 2011;54:260-275.
62. Gonzalez EW, Polansky M, Lippa CF, Walker D, Feng D. Family caregivers at risk: who are they? Issues Ment Health Nurs 2011;32:528-536.
63. Stubbs B. Displays of inappropriate sexual behaviour by patients with progressive cognitive impairment: the forgotten form of challenging behaviour? J Psychiatr Ment Health Nurs 2011;18:602-607.
64. Helmeke C, Seidel K, Poeggel G, Bredy TW, Abraham A, Braun K. Paternal deprivation during infancy results in dendrite- and time-specific changes of dendritic development and spine formation in the orbitofrontal cortex of the biparental rodent Octodon degus. Neuroscience 2009;163:790-798.
65. Poeggel G, Nowicki L, Braun K. Early social deprivation alters monoaminergic afferents in the orbital prefrontal cortex of Octodon degus. Neuroscience 2003;116:617-620.
66. Shany-Ur T, Rankin KP. Personality and social cognition in neurodegenerative disease. Curr Opin Neurol 2011;24:550-555.
67. Yan JH, Rountree S, Massman P, Doody RS, Li H. Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. J Psychiatr Res 2008;42:1203-1212.
68. Ameli M, Kemper F, Sarfeld AS, Kessler J, Fink GR, Nowak DA. Arbitrary visuo-motor mapping during object manipulation in mild cognitive impairment and Alzheimer's disease: a pilot study. Clin Neurol Neurosurg 2011;113:453-458.
69. Okanoya K, Tokimoto N, Kumazawa N, Hihara S, Iriki A. Tool-use training in a species of rodent: the emergence of an optimal motor strategy and functional understanding. PLoS ONE 2008;3:e1860.
70. Ishibashi H, Hihara S, Iriki A. Acquisition and development of monkey tool-use: behavioral and kinematic analyses. Can J Physiol Pharmacol 2000;78:958-966.
71. Brown C, Donnelly TM. Cataracts and reduced fertility in degus (Octodon degus). Contracts secondary to spontaneous diabetes mellitus. Lab Anim (NY) 2001;30:25-26.
72. Ebensperger LA, Ramírez-Estrada J, León C, et al. Sociality, glucocorticoids and direct fitness in the communally rearing rodent, Octodon degus. Horm Behav 2011;60:346-352.
73. Redy PH. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res 2012;1415:136-148.
74. Gilley J, Adalbert R, Coleman MP. Modelling early responses to neurodegenerative mutations in mice. Biochem Soc Trans 2011;39:933-938.
75. Balducci C, Forloni G. APP transgenic mice: their use and limitations. Neuromolecular Med 2011;13:117-137.
76. Kokjohn TA, Roher AE. Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement 2009;5:340-347.